Description of business

Destiny Pharma plc is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Destiny Pharma’s Vision is of an expanding range of anti-microbial drug products which operate within existing antibiotic markets but due to their unique features, open significant, new markets that are closed to traditional antibiotics due the existence or threat of antibiotic resistance.

Its proprietary, anti-microbial drug platform, the XF Drugs Series, act via an ultra-rapid action which kill bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance response

Further company information can be obtained here

Names and details of directors

Please click here for the names and brief biographical details for the directors together with a description of their responsibilities

Responsibilities of directors & committees

Please click here for information on the Audit Committee, Remuneration Committee and Nomination Committee together with the membership of those committees

Country of incorporation and operation

Destiny Pharma plc is incorporated in England and Wales and the UK is the Company’s main country of operation. Details of the Company’s registered office can be found here

The Company’s Articles of Association can be downloaded here

Shares in Destiny Pharma plc are not traded on any exchanges or trading platforms other than the AIM market

Please click here for details of the number of securities in issue, the number of securities held as treasury shares and, insofar as the Company is aware, the percentage of securities that is not in public hands together with the identity and percentage holdings of significant shareholders

Please click here for access to the Company’s annual and interim reports

Please click here to access the notifications made by the Company

The admission document can be downloaded here

The Board fully supports the underlying principles of corporate governance contained in the UK Corporate Governance Code, notwithstanding that, as its securities are not listed on the Official List, it is not required to comply with such recommendations. It has sought to comply with the provisions of the Corporate Governance Code, insofar as is practicable and appropriate for a public company of its size and nature, and recognises its overall responsibility for the Company’s systems of internal control and for monitoring their effectiveness

The Company is subject to the UK City Code on Takeovers and Mergers (the City Code) issued and administered by the Panel on Takeovers and Mergers (the Takeover Panel)

Please click here  for information on the Company’s advisers, including contact details